## InsideRetina Directory

Paso Robles Office

220 Oak Hill Rd.

(805) 237-1610

San Luis Obispo Office

3855 Broad Street,

(805) 781-0292

Santa Maria Office

(805) 922-2068

Valencia Office

Ste. 170

1510 E. Main St.,

Santa Maria, CA 93454

27420 Tourney Rd.,

Valencia, CA 91355

5405 W. Cypress Ave.,

Visalia, CA 93277

(559) 627-5200

(661) 253-2939

Visalia Office

San Luis Obispo, CA 93401

Suite B,

Paso Robles, CA 93446

#### Santa Barbara Offices

525 E. Micheltorena St. Santa Barbara, CA 93103 (805) 963-1648

4151 Foothill Rd., Santa Barbara, CA 93110 (805) 681-8950

## **Research Foundation**

525 E. Micheltorena St. Santa Barbara, CA 93103 (805) 884-5185

#### **Bakersfield Office**

5329 Office Center Ct., Bakersfield, CA 93309 (661) 325-4393

#### Lompoc Office

611 E. Ocean Ave. Lompoc, CA 93436 (805) 740-3080

#### Oxnard Office

1801 N. Solar Dr., Ste. 145 Oxnard, CA 93030 (805) 983-8808

#### Palmdale Office

38660 Medical Center Dr., Suite A-350 Palmdale, CA 93551 (661) 951-9519

## Find more information, visit us online at www.californiaretina.com

**InsideReting** Staff

Dante J. Pieramci, M.D.

Medical Director

Gabriel Gordon, PhD

Director of Research

Ann Pieramici

Managing Editor

Paul Degrow

Chief Operating Officer

## EYE SIGHTINGS AND ANNOUNCEMENTS

DR. ROBERT AVERY was awarded the American Academy of Ophthalmology's Senior Achievement Award for his "commitment to advancing the profession and positively impacting patients' eye

DR. ROBERT AVERY was also an invited guest speaker at University of Vienna's Retina Meeting and at a meeting in Zurich, where he spoke about his pioneering research with DRCR network's protocol S study used to treat proliferative diabetic retinopathy. Dr. Avery was the first physician to use anti-VEGF agents in the treatment of this disease more than 10 years ago. He also spoke at the Hawaii Eye Meeting discussing micropulse laser and lectured at ARVO and the Aspen Retinal Detachment Meeting. Last, he attended a meeting of previous chief residents of the Wilmer Institute at Johns Hopkins Hospital.

DR. ALESSANDRO CASTELLARIN attended the Aspen Retinal Detachment Society Meeting and presented research related to macular degeneration and diabetic retinopathy in Los Angeles. This summer, he will lecture on macular degeneration, vascular occlusions and retinal detachments in Italy and will attend the American Society of Retina Specialists Meeting in San Francisco.



DR. DILSHER DHOOT served on an expert panel at the Vitreous Buckle Society Meeting in Miami and presented talks at the North Coast Retina Meeting in Cleveland, ARVO in Seattle and smaller conferences in New Jersey

DR. DANTE PIERAMICI presented at the Vail Vitrectomy Meeting on rational post-operative restrictions following retinal detachment repair. He also presented research on the pathophysiology of geographic atrophy and potential therapies to local retina specialists in Palo Alto and Phoenix.

DR. NATHAN STEINLE has given educational lectures at the American Uveitis Society Meeting in Utah, the University of Kentucky, the Cleveland Clinic, and in Seattle. His presentation at ARVO was given a prestigious Hot Topic distinction and won an international award for Best of ARVO. He also attended retina meetings in Miami and Chicago.

#### CALIFORNIA RETINA RESEARCH FOUNDATION

525 E. Micheltorena Street Santa Barbara, CA 93103

## REGENERATIVE THERAPIES AT CRC OFFER HOPE TO REDUCE BLINDNESS

Cell Therapy. The use of stem cells has long been touted as a potential theraal-world applications. California Retina Consultants is proud to be participating in pioneering two regenerative cell therapy studies – both for the treatment of advanced AMD.

One, a geographic atrophy study, is sponsored by Regenerative Patch Tech-

specific cells or cell products to dis- UCSB. This trial is already recruiting eased tissue with the hopes of restoring patients in Los Angeles and CRC will function of that tissue. One such ther- participate as a follow-up site withapy getting a lot of press today is *Stem* in the next few months. The trial uses differentiated human embryonic stem cells, which will be seeded on a mempy for the treatment or prevention of brane and implanted in the retina to many eye diseases. What was for de- reduce the progression of geographic cades possible only in science fiction atrophy. The hope is that this treatment novels is now on the threshold of re- will improve the structure and function of the retina.

The second study, sponsored by Janssen, will use more differentiated human umbilical cord cells to treat geographic atrophy secondary to dry AMD. These cells will be injected sub-retinally with the hope that they will survive and nologies in collaboration with the help sustain the retinal pigment epi-

Regenerative medicine aims to deliver University of Southern California and thelial layer, photoreceptors, and other cells in the neurosensory retina. With this approach, the implanted cells will function in more supportive roles as opposed to direct cellular replacement.

> CRC is excited to be able to offer this progressive research to our patients in California. Trial space is limited, so please contact the CRC study department to inquire about enrollment and eligibility at (805) 963-1648 (ask for Gina, Sarah, or Gabe).



# InsideRetina

# ANNUAL EDUCATION MEETING WELCOMES THREE WORLD CLASS RETINA SPECIALISTS

**VOLUME 2, 2016** 



Meeting hosted by the California Retina Research Foundation welcomes three prominent guest speakers, who will share their views on the latest advancements in the treatment of retinal diseases.

Dr. Dean Elliot, associate director of the Massachusetts Eve and Ear Infirmary (Harvard University Medical School), will speak specifically about new options for patients with retinal detachments. Dr. Andrew Moshfeghi, associate professor of ophthalmology at the University of Southern California will speak on the impact of cataract surgery on patients with macular diseases. His brother, Dr. Darius Moshfeghi, professor of ophthalmology at Stanford University will discuss Zika, microcephaly and ophthalmic repercussions of the disease. The meeting will also hold a mini-symposium on diabetes, providing updates on two interesting trials sponsored by the DRCR- NEI network, a surgical/case presentation panel, and other lectures, including the cutting edge research on stem cell therapies for retinal diseases.

The California Retina Research Foundation (CRRF) has hosted this meeting for the past 14 years, educating local ophthalmologists, optometrists and associated health care professionals about forward-looking therapies for retinal diseases. CRRF is proud to work in partnership with the National Institute for Health (NIH), Johns Hopkins University, USC, and various pharmaceutical companies in providing patients on the this meeting.

For the first time in its 15-year history, the Annual Education Drs. See, Nasir, Couvillion, Avery, Castellarin, Pieramic, Dhoot and Steinle surround Dr. Steven Yeh, last year's invited speaker from the Emory Eye Center, who spoke about the Ebola virus in the eye.







Drs. Darius Moshfeghi, Andrew Moshfeghi and Dean Elliot bring their knowledge and expertise from their respective institutions: Stanford Medical Center, USC Roski Eye Institute and Harvard Eve Institute, when they address the ophthalmic community in

Central Coast and Valley access to national and international clinical trials as well as early phase evaluations of promising

The meeting takes place on Saturday, September 24th at the Fess Parker Doubletree Resort in Santa Barbara and is open to eye care professionals. For more information or to register, visit www.californiaretinaresearch.org. Registration will open on July 1, 2016. Please feel free to contact Gabriel Gordon, director of the research foundation, at 805-884-5185 or gabe@californairetina.com with any questions about

## **RESEARCH STAFF WELCOMES NEW EMPLOYEES**

The research department in Santa Barbara would like to welcome Tim Do and Kevin Card. Tim graduated from UCSB in June with a bachelor's degree in biopsychology, and a minor in applied psychology. In his spare time, Tim enjoys swimming, hiking and playing the piano. He hopes to absorb as much as he can at CRRF and apply to medical school in the future. Kevin Card is a senior biochemistry major at UCSB, also planning for a future in medicine. His interest in the field was sparked after undergoing a traumatic ophthalmic experience. He began his time at CRC as an intern, and is looking forward to being an official staff member in the research department. Beyond school and work, Kevin plays the sitar in UCSB's Indian Music Ensemble. He also enjoys spending time outside camping and paddle boarding.



Tim Do recently research staff at the California Retina Research Foundation where he looks forward to learning all he can before applying to medical school.



**UCSB** senior Kevin Card is delighted to get promoted from interning to joining the California Retina Research Foundation staff

## WHERE ARE THEY NOW?



ERICA MORASSE left CRC in April of 2016 to spend time traveling in Southeast Asia before starting graduate school for psychology.

CRC in May of 2015 to enroll in a Master's program in Nursing at UC San Francisco. She has had the opportu-



nity to do clinical rotations at Stanford and is enjoying all of the good food and culture that the city has to offer. While studying for her RN

license test she is also planning her wedding as she recently got engaged!



LISHA WAN left CRC in June of 2014 to start a Doctor of Optometry program at Southern California College of Optometry. Over the last two years she has worked with colleagues to run vision screenings at local schools. Lisha starts seeing patients in primary care this summer and is also recently engaged.

We are grateful for all past research employees and wish them the best in their future endeavors.

## **EDUCATION** & **SUPPORT MEETING**

FRIDAY, JULY.22.2016

Discussion led by: Pam Beckman-Lyon [A Certified Diabetes Counselor & Marriage and Family Therapist living with Diabetes & Visual Impairment] relationship with your health care providers! Get support, questions answered, & connect with others who share similar concerns & experiences with the doctors they see for their visual complications from Macular Degeneration to Diabetic



*Ioin us on the 3<sup>rd</sup>* floor Conference Room @

525 E. Micheltorena Santa Barbara

Time:

10:30AM-11:30AM Refreshments will be provided

family and friends welcome!



# DOCTORS AND RESEARCH STAFF SHARE THEIR EXPERTISE AT ONE OF THE LARGEST, NATIONAL EYE **RESEARCH MEETINGS**

Researchers at CRC hit the Pacific Northwest this past May to attend the Association for Research in Vision and Ophthalmology (ARVO) annual conference in Seattle, Washington. ARVO was founded by 73 ophthalmologists in 1928, and has since grown to become the largest and most respected eye and vision research organization in the world. Drs. Avery, Pieramici, Steinle and Dhoot joined over 10,000 other attendees at the Seattle convention center along with research staff members Sarah Fishbein, Jack Giust, Larissa Halsell, Gina Hong and Dr. Gabriel Gordon.



Dr. Nathan Steinle lecturing at the Association for Research in Vision and Ophthalmology (ARVO) annual conference in Seattle

Dr. Nathan Steinle delivered a lecture on vitreomacular traction syndrome (VMT), speaking about current treatments for VMT, such as ocriplasmin, Steinle also educated a nearly packed room on a novel method for grading the severity of the traction he calls the California quake?

Dr. Dante Pieramici lectured on treatment strategies for diabetic macular edema (DME) and geographic atrophy associated with dry age-related macular degeneration. For the dis-

cussion on DME, Dr. Pieramici was part of a three-person panel that delved into the currently published research for treatments and practical clinical applications. The highlight however, was Dr. Pieramici's talk about the science behind lampalizumab, the drug being investigated in two phase III clinical trials, Chroma and Spectri. Lamaplizumab is under development as a potential therapy for geographic atrophy associated with AMD. Lamaplizumab was a hot topic at this year's convention, as there are currently no FDA-approved treatments for this blinding disorder and doctors are hopeful that this effective drug will gain approval.

Dr. Avery helped put together a seminar on the treatment of diabetic macular edema, neovascular (wet) macular degeneration, and retinal vein occlusion. He was one of five This should enable more patients to be eligible for therapy, experts rendering their opinion on how to manage patients



CRC study coordinators Sarah Fishbein, Jack Giust, Larissa Halsell, and Gina Hong pose in front of the poster Sarah presented this year.

with these retinal diseases during this 90-minute special session. And CRC was excited to have Gina Hong and Sarah Fishbein present a research poster. The topic was a comparison of research findings versus real world findings. They fluid-gas exchange using C3F8 or SF6 found that the vision outcome for patients treated for DME gases, and surgical intervention. Dr. does equate to the recent findings in DRCR's pivotal Protocol T trial. The research staff attended myriad lectures and presentations addressing treatments, new perspectives on disease causality, and insights into forthcoming research for a number of diseases and disorders of the retina. This professional development directly benefits patients as the CRC staff stays current on the latest treatment options

> Forthcoming trials that were discussed include the Diabetic Retinopathy Clinical Research Network's (DRCR.net) Protocol W, a new trial aimed at stopping high-risk diabetic retinopathy patients from developing the more severe form of the disease known as proliferative diabetic retinopathy or PDR. Drs. Pieramici and Dhoot, along with Dr. Gabriel Gordon and Jack Giust attended the investigator's meeting for the Chroma and Spectri trials. Currently CRC has roughly 25 patients enrolled between these two trials for dry AMD.

New details emerged during the investigator's meeting about an extension study that will take place once a subject has completed the Chroma or Spectri trials. All currently enrolled patients will be eligible to enroll in this new Omaspect trial, a trial in which everyone will receive the experimental drug lampalizumab. Additional trials for the drug are also planned if the results of these pivotal trials prove positive. years before FDA approval.

# **EDUCATION AND SUPPORT GROUPS** OFFER GUIDANCE, ADVICE AND SOLACE

The California Retina Research Foundation continues to offer two ongoing support groups to those who face the daily fears and challenges from visual impairment. Over the past few months, the group members have established a strong bond by sharing their personal struggles and learning from others how to cope with and manage their lifestyle changes.

The Bakersfield discussion group meets the 3rd Thursday of every other month. The next meeting will take place on Thursday July 21st from 5:00-6:00pm in the Bakersfield office. Mrs. Etta Robin, a licensed marriage and family therapist, voluntarily leads this support group. Etta shares that, "the meetings continue to provide ongoing genuine support and as we become better acquainted, I believe that the participants become increasingly comfortable sharing their assorted challenges with one another."

The Santa Barbara discussion group is held every other month and is led by the research team as well as Pam Beckman-Lyon, a licensed marriage and family therapist and a certified diabetes counselor. The next meeting takes place on Friday July 22nd from 10:00-11:00am in the 3rd floor conference room. At this meeting we will discuss how to establish and maintain a positive and proactive doctor-patient relationship. We will include tips on how to prepare for your doctor visits, dealing with wait times, and how to effectively communicate your concerns and needs to your health care providers.

When asked how these groups have been going, one member states, "My mother's vision and hearing are both severely impaired. With the struggles that accompany such loss, it has been helpful to come to this new educational support group not only to hear what the facilitators have prepared, but to also glean what the participants themselves bring to the discussions. Through these seminars my mother and I continue to expand our growing resources as we join others in coping with the hardships of vision loss."

We hope to eventually expand our discussion groups to local nursing homes and retirement communities so that we can bring together others in our community who live with the anxiety and frustration from vision loss but are unable to find transportation to our offices.

If you have questions regarding the Bakersfield support group, please contact Etta Robin at (661) 319-6604 or earob62@pacbell.net. For questions regarding the Santa Barbara support group, please contact Gina Hong or Sarah Fishbein at (805) 963-1648 or ginah@californiaretina.com and sarahf@californiaretina.com. The doors at California Retina Consultants are always open to those seeking support or wanting to learn how to manage their visual impairments. And not only do we encourage existing patients to attend, but welcome all who are interested!

## California Retina Research Foundation Our Mission is Improving Your Vision

mission with a donation of:

□ \$50

□ \$250

Yes, I am interested in supporting your

□ \$100

□ \$500

□ \$1,000	□ \$2,500
□ Other \$	
My gift is in	
□ memory of	□ honor of
□ I prefer to remain	anonymous
Credit card:	
Name on Credit Card:	
Card No.:	
Exp. Date:	
Security Code:	
allowed by law. Gifts of a special person. A	y tax-deductible to the fullest extent may be arranged in memory or honor rrangements can be made to include th Will and Testament. CRFF is a 501(c)(3)
Name:	
·	opear in any printed acknowledgements)
Address:	
City:	

Please make checks payable to CRRF.

Please detach and mail to: California Retina Research Foundation 525 E. Micheltorena St., Suite D Santa Barbara, CA 93103